NCT05485870

Brief Summary

Identify the pathogenic factors involved in the occurrence and development of panvascular disease and its pathogenesis.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2022

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 1, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 3, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 31, 2024

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

August 3, 2022

Status Verified

August 1, 2022

Enrollment Period

2.1 years

First QC Date

August 1, 2022

Last Update Submit

August 1, 2022

Conditions

Panvascular Diseases

Outcome Measures

Primary Outcomes (1)

  • Any new stroke events

    Incidence of any new ischemic or hemorrhagic stroke

    Up to 48 months

Study Arms (2)

Panvascular disease group

patients with panvascular diseases

Healthy controls

Healthy controls

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients with panvascular diseases

You may qualify if:

  • \. Patients with panvascular diseases; 2. Patients or guardians who agreed to join the study; 3. Patients who can complete the relevant examinations involved in this study;

You may not qualify if:

  • patients with coagulation dysfunction.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Tiantan Hospital Capital Medical University

Beijing, Beijing Municipality, 100000, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

blood, feces, urine, saliva, tissue samples

Central Study Contacts

Peicong Ge, MD

CONTACT

15010545727gepeicong@163.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 1, 2022

First Posted

August 3, 2022

Study Start

July 1, 2022

Primary Completion

July 31, 2024

Study Completion

December 31, 2024

Last Updated

August 3, 2022

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)